AI Article Synopsis
- Mucinous borderline ovarian tumors (MBOTs) generally have a low chance of recurrence and a favorable outlook, although some can progress to mucinous ovarian carcinomas (MOCs).
- A specific case is discussed where an MBOT recurred as an invasive MOC within three years.
- Whole-exome sequencing revealed similar genetic mutations in both the original MBOT and the recurrent MOC, with the latter showing a higher burden of copy number alterations, suggesting that these genetic changes may drive the progression from MBOT to MOC.
Article Abstract
Unlabelled: Mucinous borderline ovarian tumors (MBOTs) have a very low recurrence rate and a good prognosis, especially in the early stages, but some MBOTs occasionally recur with the progression to mucinous ovarian carcinomas (MOCs). Here, we present a case of MBOT that recurred as invasive MOC within 3 years. To examine the reason for the progression from MBOT to MOC, whole-exome sequencing of our case identified identical mutations and copy number alterations in , , and in both the MBOT and recurrent MOC. The recurrent MOC had a greater copy number alteration burden compared to the primary MBOT. These findings suggest that MBOT may have progressed to MOC via recurrence, wherein the increased burden of copy number alterations could be its key driver. It was also suggested that mutations already present in MBOT may contribute to the increased copy number alterations leading to MOC.
Supplementary Information: The online version contains supplementary material available at 10.1007/s13691-024-00722-1.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11464969 | PMC |
| http://dx.doi.org/10.1007/s13691-024-00722-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!